Lisocabtagene maraleucel (liso-cel; formerly JCAR017) is an autologous anti-CD19 CAR-T containing a 41BB signaling domain with a defined and separately administered CD4+ and CD8+ CAR-T dose currently under development for the treatment of B cell malignancies, including adult patients with r/r DLBCL and MCL. The gene discussed is CD19; the disease is mantle cell lymphoma.